Perioperative versus adjuvant management of gastric cancer, update 2013
|
|
- Emil Baldwin
- 5 years ago
- Views:
Transcription
1 Perioperative versus adjuvant management of gastric cancer, update 2013 Cornelis J.H. van de Velde, MD, PhD,FRCPS and FACS,Hon. Professor of Surgery President ECCO - the European Cancer Organization Past-President European Society of Surgical Oncology Leiden University Medical Center Leiden, The Netherlands
2 Reasons for multimodality treatment Post-Operative Treat occult residual metastases Successful in other tumor types Better patient selection Peri-operative Eliminating occult micrometastases early Downstaging more R0 resections Better tolerance
3 Postoperative radiotherapy
4 British Stomach Cancer Group Trial Survival after adjuvant radiotherapy or chemotherapy in resectable gastric cancer 40% R1/R2 resection 76% started RT 58% completed MAF Local recurrence rate: RT vs Surgery 32% vs 54% Hallissey et al, Lancet 1994
5 Postoperative radiotherapy Conclusion: no role in daily clinical practice
6 Postoperative chemotherapy
7 Meta-analyses on postoperative chemotherapy No. of trials No. of patients Mortality risk 95% CI Hermans, Earle, Mari, Panzini, Janunger, GASTRIC 2010: 5-year survival benefit 5% GASTRIC - Some more 2010 benefit in node-positive 17 tumors
8 GASTRIC year survival Surgery alone 49.6 % Adjuvant chemotherapy 55.3 % HR = 0.82; p < GASTRIC Group JAMA 2010; 303:
9 RCTs on postoperative chemotherapy n control vs experimental mortality risk 95% CI 5-yr OS (%) ITMO EAP + 5FU/LV vs 52 FFCD (400) 5FU/CDDP vs 47 EORTC/ ICCG 2006 GOIM 2007 GISCAD FAMTX/FEMTX vs epi/lv/5fu/vp vs FU/LV vs PELFw vs 52
10 Sakuramoto et al, NEJM 2007 Japanese trial 1059 patients Surgery (D2) vs Surgery + S1 (6 months) Conclusion: Improved survival after S-1
11 Ajani et al., JCO 2010 S-1 in the West Limited to 1 study on metastatic gastric/gej disease Better toxicity profile compared to infusional 5-FU. No improvement in OS
12 CLASSIC Study: Korea, Taiwan, China 1035 patients Randomized between: A: D2 gastrectomy B: D2 gastrectomy + postoperative capecitabine+oxaliplatin 3-year disease free-survival 3-year overall survival P < P < 0.05
13 Postoperative chemotherapy Effective, 5% increase in overall survival What about more intensive schedules?
14 Italy 2007 more intense schedule N=400 5-FU/LV vs cisplatin/epirubicine/5-fu/lv No difference in PFS/OS Cascinu et al., J Nat Canc Inst 2007; 99:
15 Italy 2012 more intense schedule N= FU/LV vs FOLFIRI + docetaxel /cisplatin No difference in overall survival HR: 1.00; 95%CI ; p=0.98 Bajetta et al., ASCO 2012; abstract LBA 4001
16 US 2011 more intense schedule CALGB N=540 R A N 5-FU/LV x 1 5-FU i.v. CI RT 5-FU/LV x 2 D O M I Z E ECF x 1 5-FU IVCI RT ECF x 2 Fuchs et al., ASCO 2011; # 4003
17 US 2011 more intense schedule No difference in overall survival Overall Survival by Arm Proportion Surviving Years from Study Entry ECF 5-FU
18 Postoperative chemotherapy Conclusions Effective, 5% increase in overall survival No evidence for more intense chemotherapy schedules Capecitabine/oxaliplatin versus 5-FU / LV?
19 Postoperative chemoradiotherapy
20 Smalley et al, IJROBP 2002
21 Intergroup 0116 trial Day FU LV RT (25x1.8 Gy) Post-operative chemoradiation vs Surgery 73 % grade ¾ toxicity 64% completed CRT 9% survival benefit Adjuvant CRT
22 Intergroup 0116 trial Criticised Complex chemoradiotherapy protocol Lack of surgical quality control 54% D0 resection Selection of patients (only R0 resection with adequate recovery) CRT might have compensated for the low number of D2 dissections
23 MacDonald, NEJM 2001, Sakuramoto, NEJM 2007 Japanese vs Intergroup 0116 study Intergroup 0116 study Japanese study red line: 60% survival, surgery only in Japanese trial
24 Kim et al, Int. J. Radiation Oncology Biol. Phys 2005 Korean observational study 1000 patients Surgery (D2) vs Surgery + Intergroup 0116 CRT schedule Conclusion: CRT associated with improved OS after D2 surgery
25 Dutch Observational study 785 patients Surgery or Surgery + Postoperative CRT Capecitabine or capecitabine+cisplatin D1 Surgery (P = 0.04) D2 Surgery (P = NS) Conclusion: CRT associated with improved survival after D1, but not after D2 surgery
26 Dikken van de Velde et al JCO 2010 May 10;28(14): and unpubl Dutch Observational Study Overall Survival Local recurrence D1 D1: HR 1.68 P=0.04 D1: HR 14.6 P<0.01 Conclusion Adjuvant CRT has survival/ recurrence benefit over D1 BUT NOT over D2 surgery D2 D2: HR 0.88 P=0.65 D2: HR 0.98 P=0.96
27 Dikken vd Velde et al, JCO 2010 Dutch Observational study R0-resection HR 1.04 P=0.85 R1-resection HR 3.16 P<0.01
28 Gastric cancer: 15-Year follow-up Dutch D1D2 Trial 711 Patients with curative resection Overall Survival D1: 21% D2: 29% P=0.3 Local recurrence D1: 22% D2: 12%
29 15-Year follow-up Dutch D1D2 Trial Death of Gastric Cancer D1: 48% D2: 37% HR 0.74, P= Patients with curative resection Conclusion D2 dissection should be recommended as standard surgical approach in resectable gastric cancer Death of Other Causes HR=1.22, P=NS
30 Postoperative chemoradiotherapy Conclusions Significant survival benefit after D1 dissection Also after D2 dissection?
31 Preoperative radiotherapy
32 Chinese study 1998 N=370 40Gy + surgery versus surgery alone Resection rate Overall survival 30% vs 20% 90% vs 80% Operative 2.5% vs 0.6% Leakage 4.0% vs 0.8% Local recurrence 39 vs 55% Zhang et al, IJROBP 1998
33 Conclusion Preoperative radiotherapy Limited evidence Suggestion of advantage over surgery alone Only cardia cancer
34 Preoperative chemotherapy
35 Cunningham,van de Velde, NEJM 2006 MAGIC trial Peri-operative chemotherapy vs Surgery 13 % overall survival benefit 10 % more resectability
36 Intergroup 0116 vs MAGIC Intergroup 0116 Randomization after R0 surgery after diagnosis Preoperative therapy not applicable A: ECF (3 courses) B: none Completed preoperative therapy not applicable 86% Surgery D0 gastrectomy: 54% D1 gastrectomy: 36% D2 gastrectomy: 10% R0 resection 100% (if R1/R2: no inclusion) Postoperative Therapy A: 5-FU/LV/RT (45Gy) B: none Completed postoperative therapy 64% 42% Surgery Radiotherapy Result primary endpoint (experimental versus control) D2 recommended Postoperative analysis of extent of LN dissection Central review of RT plan Major deviations corrected A: 42% 5-year OS B: 25% 5-year OS MAGIC oesophagogastrectomy: 23% D1 gastrectomy: 19% D2 gastrectomy: 40% non-curative/unknown: 18% A: 69.3% B: 66.4% A: ECF (3 courses) B: none not reported not applicable A: 36% 5-year OS B: 23% 5-year OS
37 Intergroup 0116 vs MAGIC Studies are incomparable due to selection Intergroup 0116: R0 and adequate postoperative recovery MAGIC: Eligible for surgery Focus on compliance MAGIC: 85% preoperative therapy 42% total regimen Intergroup 0116: 64% CRT regimen
38 Biffi et al, World J Gastroenterol 2010 Swiss-Italian study 70 patients Randomized between: A: Preoperative chemotherapy B: Postoperative chemotherapy Results: Compliance A: 75% Compliance B: 34% Conclusion: Preoperative therapy associated with better compliance
39 R Tissue banking CRITICS (ChemoRadiotherapy after Induction ChemoTherapy in Cancer of the Stomach) Preoperative Trial:n=600 chemotherapy 3x ECC Preoperative chemotherapy 3x ECC D1 + surgery QoL D1 + surgery At least 15 nodes, No splenectomy Postoperative Chemotherapy 3x ECC Chemoradiation 45 Gy/25fx + Capecitabine + Cisplatin Quality assurance - Surgery: surgical audit to individual surgeons - Pathology: pathology audit to individual pathologists - Radiotherapy: check of RT plan before start of treatment RT atlas
40 Principle investigators Prof. M. Verheij Dr. A. Cats Prof. C.J.H. van de Velde For further information on the CRITICS trial Study coördinator Anouk Trip
41 ARTIST study: Korea 458 patients Randomized between: A: D2 gastrectomy + capecitabine + cisplatin B: D2 gastrectomy + capecitabine + cisplatin + radiotherapy 3-year disease free-survival 3-year disease free-survival all patients N+ patients P = P = 0.036
42 Conclusions Asia: most patients receive postoperative therapy S-1 in Japan Capecitabine/oxaliplatin or chemoradiotherapy in Korea USA: perioperative chemotherapy and postoperative chemoradiotherapy Europe: mostly perioperative chemotherapy
43 Conclusions Preoperative chemotherapy recommended Higher compliance More R0 resections When tolerated: postoperative therapy High risk for locoregional relapse (R1) Postoperative chemoradiotherapy High risk for distant metastases (difficult to identify) Postoperative systemic chemotherapy
44 Amsterdam September Multidisciplinary care: can we do better?
Advances in gastric cancer: How to approach localised disease?
Advances in gastric cancer: How to approach localised disease? Andrés Cervantes Professor of Medicine Classical approach to localised gastric cancer Surgical resection Pathology assessment and estimation
More informationWhich Treatment Approach is Most Appropriate for Primary Therapy of Gastric Cancer: Neoadjuvant Chemotherapy
Which Treatment Approach is Most Appropriate for Primary Therapy of Gastric Cancer: Neoadjuvant Chemotherapy Joseph Chao, M.D. Assistant Clinical Professor Department of Medical Oncology & Therapeutics
More informationThe role of chemoradiotherapy in GE junction and gastric cancer. Karin Haustermans
The role of chemoradiotherapy in GE junction and gastric cancer Karin Haustermans Overview Postoperative chemoradiotherapy Preoperative chemoradiotherapy Palliative radiation Technical aspects Overview
More informationGastroesophag Gastroesopha eal Junction Adenocarcinoma: What is the best adjuvant regimen? Michael G. G. H addock Haddock M.D.
Gastroesophageal Junction Adenocarcinoma: What is the best adjuvant regimen? Michael G. Haddock M.D. Mayo Clinic Rochester, MN Locally Advanced GE Junction ACA CT S CT or CT S CT/RT Proposition Chemoradiation
More informationNeo- and adjuvant treatment for gastric cancer: The role of chemotherapy
Anna Dorothea Wagner, PD & MER Department of Oncology University of Lausanne Neo- and adjuvant treatment for gastric cancer: The role of chemotherapy Structure 1. Background and overview 2. Adjuvant chemotherapy:
More informationNeo- and adjuvant treatment for gastric cancer: The role of chemotherapy
Neo- and adjuvant treatment for gastric cancer: The role of chemotherapy Priv. Doz. Dr. Dr. med. T.O. Götze Institute of Clinical Cancer Research Director: Prof. Dr. S.-E. Al- Batran University Cancer
More informationintent treatment be in the elderly?
Gastric cancer: How strong can curative intent treatment be in the elderly? Caio Max S. Rocha Lima, M.D. Professor of Medicine University of Miami & Sylvester Cancer Center Gastric cancer: epidemiology
More informationThe following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only.
The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only. If you have any ques7ons, please contact Imedex via email at:
More informationOverview on Gastric Cancer
Chapter 5 Role of postoperative chemoradiotherapy in the therapeutic management of adenocarcinomas of the stomach and oesogastric junction Ben Salah H*; Bahri M; Dhouib F; Sallemi N; Bourmèche M; Daoud
More informationImpact of upfront randomization for postoperative treatment on quality of surgery in the CRITICS gastric cancer trial
Gastric Cancer (219) 22:369 376 https://doi.org/1.7/s112-18-875-1 ORIGINAL ARTICLE Impact of upfront randomization for postoperative treatment on quality of surgery in the CRITICS gastric cancer trial
More informationAdjuvant Chemotherapy for Rectal Cancer: Are we making progress?
Adjuvant Chemotherapy for Rectal Cancer: Are we making progress? Hagen Kennecke, MD, MHA, FRCPC Division Of Medical Oncology British Columbia Cancer Agency October 25, 2008 Objectives Review milestones
More informationADJUVANT CHEMOTHERAPY FOR RECTAL CANCER
ESMO Preceptorship Programme Colorectal Cancer Barcelona November, 25-26, 2016 ADJUVANT CHEMOTHERAPY FOR RECTAL CANCER Andrés Cervantes Professor of Medicine OLD APPROACH TO RECTAL CANCER Surgical resection
More informationMedicinae Doctoris. One university. Many futures.
Medicinae Doctoris The Before and The After: Can chemotherapy revise the trajectory of gastric and esophageal cancers? Dr. David Dawe MD, FRCPC Medical Oncologist Assistant Professor Disclosures None All
More informationAn update of adjuvant treatments for localized advanced gastric cancer
Review An update of adjuvant treatments for localized advanced gastric cancer Clin. Invest. (2012) 2(11), 1101 1108 Although adjuvant therapy has become the standard of care worldwide for resectable localized
More informationTreatment of resectable gastric cancer
Therapeutic Advances in Gastroenterology Review Treatment of resectable gastric cancer Johan L. Dikken, Cornelis J.H. van de Velde, Daniel G. Coit, Manish A. Shah, Marcel Verheij and Annemieke Cats Abstract:
More informationCarcinoma del retto: Highlights
Carcinoma del retto: Highlights Stefano Cordio Struttura Complessa di Oncologia Medica ARNAS Garibaldi Catania Roma 17 Febbraio 2018 Disclosures Advisory Committee, research funding and speakers bureau
More informationChemoradiotherapy Versus Chemotherapy for Localized Gastric Cancer: A Mini Review
www.rarediseasesjournal.com Journal of Rare Diseases Research & Treatment Mini-review Open Access Chemoradiotherapy Versus Chemotherapy for Localized Gastric Cancer: A Mini Review Daniel da Motta Girardi
More informationRadiotherapy for rectal cancer. Karin Haustermans Department of Radiation Oncology
Radiotherapy for rectal cancer Karin Haustermans Department of Radiation Oncology O U T L I N E RT with TME surgery? Neoadjuvant or adjuvant RT? 5 x 5 Gy or long-course CRT? RT with new drugs? Selection
More informationACR Appropriateness Criteria Resectable Stomach Cancer
ACR Appropriateness Criteria Resectable Stomach Cancer Review Article [1] August 15, 2015 Oncology Journal [2], Gastrointestinal Cancer [3] By Parima Daroui, MD, PhD [4], Salma K. Jabbour, MD [5], Joseph
More informationNEOADJUVANT THERAPY IN CARCINOMA STOMACH. Dr Jyotirup Goswami Consultant Radiation Oncologist Narayana Superspeciality Hospital, Howrah
NEOADJUVANT THERAPY IN CARCINOMA STOMACH Dr Jyotirup Goswami Consultant Radiation Oncologist Narayana Superspeciality Hospital, Howrah NEOADJUVANT THERAPY?! Few believers Limited evidence Many surgeons
More informationSystemic treatment in early and advanced gastric cancer
Systemic treatment in early and advanced gastric cancer Andrés Cervantes Professor of Medicine Classical approach to localised gastric cancer n Surgical resection n Pathology assessment and estimation
More informationRole of lymph node ratio in selection of adjuvant treatment (chemotherapy vs. chemoradiation) in patients with resected gastric cancer
Original Article Role of lymph node ratio in selection of adjuvant treatment (chemotherapy vs. chemoradiation) in patients with resected gastric cancer Brice Jabo 1, Matthew J. Selleck 2, John W. Morgan
More informationWhat Is The Optimal Adjuvant Therapy in Pancreatic Adenoca: Intensified Chemotherapy March 28 th, 2015
What Is The Optimal Adjuvant Therapy in Pancreatic Adenoca: Intensified Chemotherapy March 28 th, 2015 Eileen M. O Reilly, M.D. Associate Director David M. Rubenstein Center Pancreatic Cancer Research
More informationUpper Gastrointestinal Cancers in the Elderly. Choo Su Pin Senior Consultant Medical Oncology National Cancer Centre Singapore
Upper Gastrointestinal Cancers in the Elderly Choo Su Pin Senior Consultant Medical Oncology National Cancer Centre Singapore Gastric Cancer --High Global Burden Global Cancer Deaths % of all cancer (2008)
More information(Neo-) adjuvant Treatment of Gastric Cancer. - The European View
(Neo-) adjuvant Treatment of Gastric Cancer - The European View Florian Lordick, MD Professor of Oncology Director of the University Cancer Center Leipzig (UCCL) University of Leipzig, Germany My Conflict
More informationLa Ricerca Clinica nei Trattamenti Integrati del Carcinoma Gastrico
XXI Congresso Nazionale AIRO Genova, 19-22 Novembre 2011 La Ricerca Clinica nei Trattamenti Integrati del Carcinoma Gastrico Antonino De Paoli UO Oncologia Radioterapica, CRO Aviano Gastric Cancer Current
More informationRob Glynne-Jones Mount Vernon Cancer Centre
ESMO Preceptorship Programme Colorectal Cancer Valencia May 2018 State of the art: Standards of care in preoperative treatment for rectal cancer Rob Glynne-Jones Mount Vernon Cancer Centre My Disclosures:
More information肺癌放射治療新進展 Recent Advance in Radiation Oncology in Lung Cancer 許峰銘成佳憲國立台灣大學醫學院附設醫院腫瘤醫學部
肺癌放射治療新進展 Recent Advance in Radiation Oncology in Lung Cancer 許峰銘成佳憲國立台灣大學醫學院附設醫院腫瘤醫學部 Outline Current status of radiation oncology in lung cancer Focused on stage III non-small cell lung cancer Radiation
More informationCover Page. Author: Dikken, Johannes Leen Title: Gastric cancer : staging, treatment, and surgical quality assurance Issue Date:
Cover Page The handle http://hdl.handle.net/1887/19858 holds various files of this Leiden University dissertation. Author: Dikken, Johannes Leen Title: Gastric cancer : staging, treatment, and surgical
More informationChemotherapy for resectable liver mets: Options and Issues. Herbert Hurwitz Duke University Medical Center Durham, North Carolina, USA
Chemotherapy for resectable liver mets: Options and Issues Herbert Hurwitz Duke University Medical Center Durham, North Carolina, USA Chemotherapy regimens in 1 st line mcrc Standard FOLFOX-Bev FOLFIRI-Bev
More information2015 EUROPEAN CANCER CONGRESS
2015 EUROPEAN CANCER CONGRESS 25-29 September 2015 Vienna, Austria SUMMARY The European Cancer Congress (ECC 2015) combined the 40th European Society for Medical Oncology (ESMO) congress with the 18th
More informationResearch Article Survival Benefit of Adjuvant Radiation Therapy for Gastric Cancer following Gastrectomy and Extended Lymphadenectomy
International Surgical Oncology Volume 2012, Article ID 307670, 7 pages doi:10.1155/2012/307670 Research Article Survival Benefit of Adjuvant Radiation Therapy for Gastric Cancer following Gastrectomy
More informationAdjuvant chemotherapy with 5-FU or regimens including oral fluoropyrimidine for curable gastric cancer
Gastric Cancer (2009) 12 (Suppl 1): 10 15 DOI 10.1007/s10120-008-0465-8 2009 by International and Japanese Gastric Cancer Associations Review article Adjuvant chemotherapy with 5-FU or regimens including
More informationPUBLISHED VERSION.
PUBLISHED VERSION Ya'nan Yang, Xue Yin, Lei Sheng, Shan Xu, Lingling Dong, Lian Liu Perioperative chemotherapy more of a benefit for overall survival than adjuvant chemotherapy for operable gastric cancer:
More informationRadiotherapy for Gastric Cancer. Nitin Ohri, M.D. Montefiore Medical Center Albert Einstein College of Medicine 12/15/2012
Radiotherapy for Gastric Cancer Nitin Ohri, M.D. Montefiore Medical Center Albert Einstein College of Medicine 12/15/2012 Disclosures I have no conflicts of interest to disclose. Outline Background Treatment
More informationAdjuvant Chemotherapy
State-of-the-art: standard of care for resectable NSCLC Adjuvant Chemotherapy JY DOUILLARD MD PhD Professor of Medical Oncology Integrated Centers of Oncology R Gauducheau University of Nantes France Adjuvant
More informationNewly Diagnosed Cases Cancer Related Death NCI 2006 Data
Multi-Disciplinary Management of Esophageal Cancer: Surgical and Medical Steps Forward Alarming Thoracic Twin Towers 200000 150000 UCSF UCD Thoracic Oncology Conference November 21, 2009 100000 50000 0
More informationApproaches to Surgical Treatment of Gastric Cancer. Byrne Lee, MD FACS Chief, Mixed Tumor Surgery Service
Approaches to Surgical Treatment of Gastric Cancer Byrne Lee, MD FACS Chief, Mixed Tumor Surgery Service Disclosures I do not have anything to disclose Outline Background Diagnosis Histology Staging Surgery
More informationBehandelingsmogelijkheden bij het maagcarcinoom: HIPEC. Johanna van Sandick, NKI-AvL, Amsterdam
Behandelingsmogelijkheden bij het maagcarcinoom: HIPEC Johanna van Sandick, NKI-AvL, Amsterdam Gastric cancer treatment with curative intent Macdonald et al. NEJM 2001 Cunningham et al. NEJM 2006 CRITICS
More information(IQR 233 (59%) (62%) ), 43 (95% CI
Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial Annemieke Cats*, Edwin
More informationDe-Escalate Trial for the Head and neck NSSG. Dr Eleanor Aynsley Consultant Clinical Oncologist
De-Escalate Trial for the Head and neck NSSG Dr Eleanor Aynsley Consultant Clinical Oncologist 3 HPV+ H&N A distinct disease entity Leemans et al., Nature Reviews, 2011 4 Good news Improved response to
More informationQiong Yang, 1 Ying Wei, 1 Yan-Xian Chen, 1 Si-Wei Zhou, 2 Zhi-Min Jiang, 1 and De-Rong Xie Introduction. 2. Methods
Gastroenterology Research and Practice Volume 2013, Article ID 634929, 7 pages http://dx.doi.org/10.1155/2013/634929 Review Article Indirect Comparison Showed Survival Benefit from Adjuvant Chemoradiotherapy
More informationstage III gastric cancer after D2 gastrectomy.
RESEARCH ARTICLE Comparison of capecitabine and oxaliplatin with S-1 as adjuvant chemotherapy in stage III gastric cancer after D2 gastrectomy Jang Ho Cho, Jae Yun Lim, Jae Yong Cho* Division of Medical
More informationDisclosures. Preoperative Treatment: Chemotherapy or ChemoRT? Adjuvant chemotherapy helps. so what about chemo first?
Disclosures Preoperative Treatment: Chemotherapy or ChemoRT? Advisory boards Genentech (travel only), Pfizer Salary support for clinical trials Celgene, Merck, Merrimack Matthew Gubens, MD, MS Assistant
More informationRadiotherapy Management of Breast Cancer Treated with Neoadjuvant Chemotherapy. Julia White MD Professor, Radiation Oncology
Radiotherapy Management of Breast Cancer Treated with Neoadjuvant Chemotherapy Julia White MD Professor, Radiation Oncology Agenda Efficacy of radiotherapy in the management of breast cancer in the Adjuvant
More informationNon-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist
Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist Vichien Srimuninnimit, MD. Medical Oncology Division Faculty of Medicine, Siriraj Hospital Outline Resectable NSCLC stage
More informationAdjuvant Treatment of Pancreatic Cancer in 2009: Where Are We? Highlights from the 45 th ASCO Annual Meeting. Orlando, FL, USA. May 29 - June 2, 2009
HIGHLIGHT ARTICLE - Slide Show Adjuvant Treatment of Pancreatic Cancer in 2009: Where Are We? Highlights from the 45 th ASCO Annual Meeting. Orlando, FL, USA. May 29 - June 2, 2009 Muhammad Wasif Saif
More informationUpper Gastrointestinal. Friday, March 2, :00 p.m. 2:45 p.m.
Upper Gastrointestinal Friday, March 2, 2018 2:00 p.m. 2:45 p.m. Social Q&A Use your phone, tablet, or laptop to Submit questions to speakers and moderators Answer interactive questions / audience response
More informationTristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease
Tristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease Jennifer E. Tseng, MD UFHealth Cancer Center-Orlando Health Sep 12, 2014 Background Approximately
More informationAre we making progress? Marked reduction in operative morbidity and mortality
Are we making progress? Surgical Progress Marked reduction in operative morbidity and mortality Introduction of Minimal-Access approaches for complex esophageal cancer resections Significantly better functional
More informationTratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón
Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón Santiago Ponce Aix Servicio Oncología Médica Hospital Universitario 12 de Octubre Madrid Stage III: heterogenous disease
More informationVan Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
Efficacy Results from the ToGA Trial: A Phase III Study of Trastuzumab Added to Standard Chemotherapy in First-Line HER2- Positive Advanced Gastric Cancer Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
More informationLocally advanced disease & challenges in management
Gynecologic Cancer InterGroup Cervix Cancer Research Network Cervix Cancer Education Symposium, February 2018 Locally advanced disease & challenges in management Carien Creutzberg Radiation Oncology, Leiden
More informationChemoradiotherapy in Gastric Cancer Chances and Challenges. Anouk K. Trip
Chemoradiotherapy in Gastric Cancer Chances and Challenges Anouk K. Trip Chemoradiotherapy in gastric cancer - chances and challenges The work described in this thesis was conducted at the Netherlands
More informationPre- Versus Post-operative Radiotherapy
Postoperative Radiation and Chemoradiation: Indications and Optimization of Practice Dislosures Clinical trial support from Genentech Inc. Sue S. Yom, MD, PhD Associate Professor UCSF Radiation Oncology
More informationUpdate on Limited Small Cell Lung Cancer. Laurie E Gaspar MD, MBA Prof/Chair Radiation Oncology University of Colorado Denver
Update on Limited Small Cell Lung Cancer Laurie E Gaspar MD, MBA Prof/Chair Radiation Oncology University of Colorado Denver Objectives - Limited Radiation Dose Radiation Timing Radiation Volume PCI Neurotoxicity
More informationPancreatic Adenocarcinoma
Pancreatic Adenocarcinoma AProf Lara Lipton 28 April 2018 Percentage alive 5 years after diagnosis for men and women Epidemiology 6% of cancer related deaths worldwide 4 th highest cause of cancer death
More informationLocally advanced head and neck cancer
Locally advanced head and neck cancer Radiation Oncology Perspective Petek Erpolat, MD Gazi University, Turkey Definition and Management of LAHNC Stage III or IV cancers generally include larger primary
More informationProphylactic Cranial Irradiation and Thoracic Radiotherapy in Extensive Stage Small-Cell Lung Cancer
Prophylactic Cranial Irradiation and Thoracic Radiotherapy in Extensive Stage Small-Cell Lung Cancer Dr Neil Bayman Consultant Clinical Oncology ESMO-Christie Preceptorship Programme in Lung Cancer, March
More informationUpdate on Neoadjuvant Chemotherapy (NACT) in Cervical Cancer
Update on Neoadjuvant Chemotherapy (NACT) in Cervical Cancer Nicoletta Colombo, MD University of Milan-Bicocca European Institute of Oncology Milan, Italy NACT in Cervical Cancer NACT Stage -IB2 -IIA>4cm
More informationسرطان المعدة. Gastric Cancer حمود حامد
سرطان المعدة Gastric Cancer ا أ لستاذ الدك تور حمود حامد عميد كلية الطب البشري بجامعة دمشق Epidemiology second leading cause of cancer death and fourth most common cancer worldwide Overall declining Histologic
More informationOpportunity for palliative care Research
Opportunity for palliative care Research Role of Radiotherapy in Multidisciplinary Management of Rectal Cancers Dr Sushmita Pathy Associate Professor Department of Radiation Oncology Dr BRA Institute Rotary
More informationHPV INDUCED OROPHARYNGEAL CARCINOMA radiation-oncologist point of view. Prof. dr. Sandra Nuyts Dep. Radiation-Oncology UH Leuven Belgium
HPV INDUCED OROPHARYNGEAL CARCINOMA radiation-oncologist point of view Prof. dr. Sandra Nuyts Dep. Radiation-Oncology UH Leuven Belgium DISCLOSURE OF INTEREST Nothing to declare HEAD AND NECK CANCER -HPV
More informationPerioperative chemotherapy: individualized therapy or same treatment for all? Prof. Dr. med. Salah-Eddin Al-Batran
Perioperative chemotherapy: individualized therapy or same treatment for all? Prof. Dr. med. Salah-Eddin Al-Batran Institute of Clinical Cancer Research Krankenhaus Nordwest UCT - University Cancer Center
More informationManagement of early rectal cancer: Any role for adjuvant chemotherapy
Management of early rectal cancer: Any role for adjuvant chemotherapy Andrés Cervantes Professor of Medicine CURRENTS CONCEPTS IN RECTAL CANCER DIAGNOSIS AND THERAPY TME surgery Optimal staging by MRI
More informationCa Cardias e Stomaco: le diversita e le terapie
XXII Riunione Nazionale I.T.M.O. Ca Cardias e Stomaco: le diversita e le terapie Maria Di Bartolomeo s.s. Oncologia Medica Gastroenterologica Fondazione IRCCS Istituto Nazionale Tumori Milano OUTLINE History
More informationPrinted by Hadi Ranjkeshzadeh on 11/12/2010 4:40:23 PM. For personal use only. Not approved for distribution. Copyright 2010 National Comprehensive
Discussion Categories of Evidence and Consensus Category 1: The recommendation is based on high-level evidence (e.g. randomized controlled trials) and there is uniform consensus. Category 2A: The recommendation
More informationNeodjuvant chemotherapy
Neodjuvant chemotherapy Dr Robert Huddart Senior Lecturer and Honorary Consultant in Clinical Oncology Royal Marsden Hospital and Institute of Cancer Research Why consider neo-adjuvant chemotherapy? Loco-regional
More information3/8/2014. Case Presentation. Primary Treatment of Anal Cancer. Anatomy. Overview. March 6, 2014
Case Presentation Primary Treatment of Anal Cancer 65 year old female presents with perianal pain, lower GI bleeding, and anemia with Hb of 7. On exam 6 cm mass protruding through the anus with bulky R
More informationGastric Carcinoma Neoadjuvant and Adjuvant Therapy
14 Gastric Carcinoma Neoadjuvant and Adjuvant Therapy Yüksel Ürün 1, Ali Ayberk Beşen 2 and Hüseyin Abalı 2 1 Ankara University School of Medicine, Department of Internal Medicine, Division of Medical
More informationCapizzello A, Tsekeris PG, Pakos EE, Papathanasopoulou V, Pitouli EJ. Correspondence to: Emilios E. Pakos,
Original Article Adjuvant chemo-radiotherapy in patients with gastric cancer Capizzello A, Tsekeris PG, Pakos EE, Papathanasopoulou V, Pitouli EJ Department of Radiation Therapy, University Hospital of
More informationCurrent standards of care in gastric cancer
Current standards of care in gastric cancer Prof Eric Van Cutsem, MD, PhD Digestive Oncology Leuven, Belgium Eric.VanCutsem@uzleuven.be Outline Resectable gastric cancer: the role of neoadjuvant and adjuvant
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/38705 holds various files of this Leiden University dissertation. Author: Gijn, Willem van Title: Rectal cancer : developments in multidisciplinary treatment,
More informationDr Roopinder Gillmore July 2017
Dr Roopinder Gillmore July 2017 Resectable Borderline / locally advanced Metastatic 15-20% 15-20% 60-70% 22-28 months 9-15 months 6-12 months Does the patient have resectable disease?? Definitely not
More informationCase Conference. Craig Morgenthal Department of Surgery Long Island College Hospital
Case Conference Craig Morgenthal Department of Surgery Long Island College Hospital Neoadjuvant versus Adjuvant Radiation Therapy in Rectal Carcinoma Epidemiology American Cancer Society statistics for
More informationRebecca K. S. Wong 1, Raymond Jang 2, Gail Darling 3. Review Article
Review Article Postoperative chemoradiotherapy vs. preoperative chemoradiotherapy for locally advanced (operable) gastric cancer: clarifying the role and technique of radiotherapy Rebecca K. S. Wong 1,
More informationPERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER. Virginie Westeel Chest Disease Department University Hospital Besançon, France
PERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER Virginie Westeel Chest Disease Department University Hospital Besançon, France LEARNING OBJECTIVES 1. To understand the potential of perioperative
More informationHigh Risk Localized Prostate Cancer Treatment Should Start with RT
High Risk Localized Prostate Cancer Treatment Should Start with RT Jason A. Efstathiou, M.D., D.Phil. Assistant Professor of Radiation Oncology Massachusetts General Hospital Harvard Medical School 10
More informationAdjuvant therapy in pancreatic cancer Monotherapy for whom? JL VAN LAETHEM, MD,PhD
Adjuvant therapy in pancreatic cancer Monotherapy for whom? JL VAN LAETHEM, MD,PhD Efficacy Parameters in adjuvant monochemotherapy Randomized studies in resectable PDAC Regimen DFS HR (p) OS HR (p) 5-yr-OS
More informationThe Role of Radiation Therapy in Upper Gastrointestinal Cancers
The Role of Radiation Therapy in Upper Gastrointestinal Cancers David H. Ilson, MD, PhD David H. Ilson, MD, PhD, is an attending physician at the Memorial Sloan Kettering Cancer Center and a professor
More informationHeather Wakelee, M.D.
Heather Wakelee, M.D. Assistant Professor of Medicine, Oncology Stanford University Sponsored by Educational Grant Support from Adjuvant (Post-Operative) Lung Cancer Chemotherapy Heather Wakelee, M.D.
More informationLeong et al. BMC Cancer (2015) 15:532 DOI /s x
Leong et al. BMC Cancer (2015) 15:532 DOI 10.1186/s12885-015-1529-x STUDY PROTOCOL Open Access TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation
More informationNeoadjuvant Therapy for Rectal Cancer is Overrated. Joon H. Lee, Research Resident University of Colorado 8/31/2009
Neoadjuvant Therapy for Rectal Cancer is Overrated Joon H. Lee, Research Resident University of Colorado 8/31/2009 Objectives Brief overview of staging rectal cancer Current guidelines for evaluation and
More informationState of the art: Standard(s) of radio/chemotherapy for rectal cancer
State of the art: Standard(s) of radio/chemotherapy for rectal cancer Dr Ian Chau Consultant Medical Oncologist The Royal Marsden Hospital London & Surrey Disclosure Advisory Board: Sanofi Oncology, Eli-
More informationPathological features as predictors of recurrence after radical resection of gastric cancer
Original article Pathological features as predictors of recurrence after radical resection of gastric cancer R. Buzzoni 1,E.Bajetta 1,M.DiBartolomeo 1,R.Miceli 2,E.Beretta 1, E. Ferrario 1 and L. Mariani
More informationPMRT for N1 breast cancer :CONS. Won Park, M.D., Ph.D Department of Radiation Oncology Samsung Medical Center
PMRT for N1 breast cancer :CONS Won Park, M.D., Ph.D Department of Radiation Oncology Samsung Medical Center DBCG 82 b & c Overgaard et al Radiot Oncol 2007 1152 pln(+), 8 or more nodes removed Systemic
More informationRole of Prophylactic Cranial Irradiation in Small Cell Lung Cancer
Role of Prophylactic Cranial Irradiation in Small Cell Lung Cancer Kazi S. Manir MD,DNB,ECMO,PDCR Clinical Tutor Department of Radiotherapy R. G. Kar Medical College and Hospital, Kolkata SCLC 15% of lung
More informationMultimodal treatment of gastric cancer
Online Submissions: http://www.wjgnet.com/esps/ wjgs@wjgnet.com doi:10.4240/wjgs.v6.i4.55 World J Gastrointest Surg 2014 April 27; 6(4): 55-58 ISSN 1948-9366 (online) 2014 Baishideng Publishing Group co.,
More informationLaryngeal Preservation Using Radiation Therapy. Chemotherapy and Organ Preservation
1 Laryngeal Preservation Using Radiation Therapy 1903: Schepegrell was the first to perform radiation therapy for the treatment of laryngeal cancer Conventional external beam radiation produced disappointing
More informationCURRENT STANDARD OF CARE IN NASOPHARYNGEAL CANCER
CURRENT STANDARD OF CARE IN NASOPHARYNGEAL CANCER Jean-Pascal Machiels Department of medical oncology Institut I Roi Albert II Cliniques universitaires Saint-Luc Université catholique de Louvain, Brussels,
More informationResectable locally advanced oesophagogastric cancer
Resectable locally advanced oesophagogastric cancer Clinical Case Discussion Florian Lordick University Cancer Center Leipzig University Clinic Leipzig Leipzig, Germany esmo.org DISCLOSURES Honoraria for
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Abdominal drainage, after hepatic resection, 159 160 Ablation, radiofrequency, for hepatocellular carcinoma, 160 161 Adenocarcinoma, pancreatic.
More informationAdjuvant therapy in older adults: controversies and challenges - Colorectal cancer -
International Society of Geriatric Oncology Lisbon October 23 rd 25t h 2014 Adjuvant therapy in older adults: controversies and challenges - Colorectal cancer - Claus-Henning Köhne Klinik für Onkologie
More informationMini J.Elnaggar M.D. Radiation Oncology Ochsner Medical Center 9/23/2016. Background
Mini J.Elnaggar M.D. Radiation Oncology Ochsner Medical Center 9/23/2016 Background Mostly adenocarcinoma (scc possible, but treated like anal cancer) 39, 220 cases annually Primary treatment: surgery
More informationWorkshop LA RADIOTERAPIA DEI TUMORI RARI I TIMOMI : INDICAZIONI
XXI CONGRESSO NAZIONALE AIRO Genova, 19-22 novembre 2011 Workshop LA RADIOTERAPIA DEI TUMORI RARI I TIMOMI : INDICAZIONI PIERA NAVARRIA Unità Operativa di Radioterapia e Radiochirurgia Humanitas Cancer
More informationWhole Breast Irradiation: Class vs. Hypofractionation
Whole Breast Irradiation: Class vs. Hypofractionation Kyung Hwan Shin, MD, PhD. Dept. of Radiation Oncology, Seoul National University Hospital 2018. 4. 6. GBCC Treatment Trends of Early Breast Cancer
More informationTreatment of gastric cancer
Online Submissions: http://www.wjgnet.com/esps/ bpgoffice@wjgnet.com doi:10.3748/wjg.v20.i7.1635 World J Gastroenterol 2014 February 21; 20(7): 1635-1649 ISSN 1007-9327 (print) ISSN 2219-2840 (online)
More informationRadiotherapy Implications of ACOSOG Z-11 for Clinical Practice. Julia White, MD Professor of Radiation Oncology Medical College of Wisconsin
1 Radiotherapy Implications of ACOSOG Z-11 for Clinical Practice Julia White, MD Professor of Radiation Oncology Medical College of Wisconsin Disclosures: none Agenda 1. ACOSOG Z-11: Another perspective
More informationAdjuvant Radiotherapy for completely resected NSCLC
Adjuvant Radiotherapy for completely resected NSCLC ESMO Preceptorship on lung Cancer Manchester February 2017 Cécile Le Péchoux Radiation Oncology Department IOT Institut d Oncologie Thoracique Local
More informationRob Glynne-Jones Mount Vernon Cancer Centre
ESMO Preceptorship Programme Colorectal Cancer Prague July 2016 State of the art: Standard of care for anal squamous cancer Rob Glynne-Jones Mount Vernon Cancer Centre Aim to discuss Background The trials
More information